Myriad Genetics (MYGN) Cash & Current Investments (2009 - 2026)

Myriad Genetics has disclosed Cash & Current Investments across 18 years of filings, most recently posting $124.4 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 35.51% year-over-year to $124.4 million; the TTM figure through Mar 2026 stood at $124.4 million (up 35.51% YoY), while the FY2025 annual figure was $149.6 million, up 46.09% from the prior year.
• Cash & Current Investments slipped to $124.4 million in Q1 2026, from $149.6 million in the prior quarter.
• Over the last five years, Cash & Current Investments for MYGN reached as high as $267.4 million in Q1 2022 and fell as low as $74.4 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $114.9 million (2022), against an average of $129.1 million.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 51.85% — and 2023, when it slumped 70.57%.
• A 5-year view of Cash & Current Investments shows it stood at $114.9 million in 2022, then advanced by 22.63% to $140.9 million in 2023, then slipped by 27.32% to $102.4 million in 2024, then soared by 46.09% to $149.6 million in 2025, then decreased by 16.84% to $124.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $124.4 million, $149.6 million, and $145.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.